Genespire is looking to take its single-dose gene therapy, GENE202, to the clinic by the end of 2026, where it will be ...

Lipocine has completed the enrolment and participant dosing in its Phase III clinical trial investigating LPCN 1154 to treat ...

The UK DRI has announced an international research study to assess whether a finger-prick blood test could help diagnose ...

Tanabe Pharma America, a subsidiary of the Tanabe Pharma Corporation, is not the only company developing drugs for EPP and ...

Adalyon’s CEO, Ulrik Zeuthen, notes that speech-based biomarkers can be used across several applications to optimise trial ...

Analysis published in the American Society of Nephrology highlighted strong evidence that ERAs benefit chronic kidney disease ...

Genmab has announced topline results from the Phase III EPCORE DLBCL-1 trial, highlighting improved PFS for its subcutaneous ...

Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...

Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.